Summary
The NAFTA Pharmaceuticals industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value 2018-22, and forecast to 2027). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
Key Highlights
- The North American Free Trade Agreement (NAFTA) is a trade agreement between the countries in North America: the US, Canada and Mexico. The pharmaceuticals industry within the NAFTA countries had a total market value of $459.6 billion in 2022.The Mexico was the fastest growing country, with a CAGR of 8% over the 2018-22 period.
- Within the pharmaceuticals industry, the US is the leading country among the NAFTA bloc, with market revenues of $408.0 billion in 2022. This was followed by Canada and Mexico, with a value of $26.1 and $25.5 billion, respectively.
- The US is expected to lead the pharmaceuticals industry in the NAFTA bloc, with a value of $463.0 billion in 2027, followed by Mexico and Canada with expected values of $37.8 and $27.3 billion, respectively.
Scope
- Save time carrying out entry-level research by identifying the size, growth, and leading players in the NAFTA pharmaceuticals market
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the NAFTA pharmaceuticals market
- Leading company profiles reveal details of key pharmaceuticals market players’ NAFTA operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the NAFTA pharmaceuticals market with five year forecasts
- Compares data from the US, Canada and Mexico, alongside individual chapters on each country
Reasons to Buy
- What was the size of the NAFTA pharmaceuticals market by value in 2022?
- What will be the size of the NAFTA pharmaceuticals market in 2027?
- What factors are affecting the strength of competition in the NAFTA pharmaceuticals market?
- How has the market performed over the last five years?
- Who are the top competitors in the NAFTA pharmaceuticals market?
'
Table of Contents
1 Introduction
1.1. What is this report about?
1.2. Who is the target reader?
1.3. How to use this report
1.4. Definitions
2 NAFTA Pharmaceuticals
2.1. Industry Outlook
3 Pharmaceuticals in Canada
3.1. Market Overview
3.2. Market Data
3.3. Market Segmentation
3.4. Market outlook
3.5. Five forces analysis
4 Macroeconomic Indicators
4.1. Country data
5 Pharmaceuticals in Mexico
5.1. Market Overview
5.2. Market Data
5.3. Market Segmentation
5.4. Market outlook
5.5. Five forces analysis
6 Macroeconomic Indicators
6.1. Country data
7 Pharmaceuticals in The United States
7.1. Market Overview
7.2. Market Data
7.3. Market Segmentation
7.4. Market outlook
7.5. Five forces analysis
8 Macroeconomic Indicators
8.1. Country data
9 Company Profiles
9.1. Johnson & Johnson
9.2. Apotex, Inc.
9.3. Sanofi SA
9.4. Genomma Lab Internacional SAB de CV
9.5. Merck & Co., Inc.
9.6. Pfizer Inc.
9.7. AstraZeneca PLC
10 Appendix
10.1. Methodology
10.2. About MarketLine
List of Tables
Table 1: NAFTA countries pharmaceuticals industry, revenue ($bn), 2018-27
Table 2: NAFTA countries pharmaceuticals industry, revenue ($bn), 2018-22
Table 3: NAFTA countries pharmaceuticals industry forecast, revenue ($bn), 2022-27
Table 4: Canada pharmaceuticals market value: $ billion, 2017-22
Table 5: Canada pharmaceuticals market geography segmentation: $ billion, 2022
Table 6: Canada pharmaceuticals market value forecast: $ billion, 2022–27
Table 7: Canada size of population (million), 2018–22
Table 8: Canada gdp (constant 2005 prices, $ billion), 2018–22
Table 9: Canada gdp (current prices, $ billion), 2018–22
Table 10: Canada inflation, 2018–22
Table 11: Canada consumer price index (absolute), 2018–22
Table 12: Canada exchange rate, 2018–22
Table 13: Mexico pharmaceuticals market value: $ billion, 2017-22
Table 14: Mexico pharmaceuticals market geography segmentation: $ billion, 2022
Table 15: Mexico pharmaceuticals market value forecast: $ billion, 2022–27
Table 16: Mexico size of population (million), 2018–22
Table 17: Mexico gdp (constant 2005 prices, $ billion), 2018–22
Table 18: Mexico gdp (current prices, $ billion), 2018–22
Table 19: Mexico inflation, 2018–22
Table 20: Mexico consumer price index (absolute), 2018–22
Table 21: Mexico exchange rate, 2018–22
Table 22: United States pharmaceuticals market value: $ billion, 2017-22
Table 23: United States pharmaceuticals market geography segmentation: $ billion, 2022
Table 24: United States pharmaceuticals market value forecast: $ billion, 2022–27
Table 25: United States size of population (million), 2018–22
Table 26: United States gdp (constant 2005 prices, $ billion), 2018–22
Table 27: United States gdp (current prices, $ billion), 2018–22
Table 28: United States inflation, 2018–22
Table 29: United States consumer price index (absolute), 2018–22
Table 30: United States exchange rate, 2018–22
Table 31: Johnson & Johnson: key facts
Table 32: Johnson & Johnson: Annual Financial Ratios
Table 33: Johnson & Johnson: Key Employees
Table 34: Johnson & Johnson: Key Employees Continued
Table 35: Apotex, Inc.: key facts
Table 36: Apotex, Inc.: Key Employees
Table 37: Sanofi SA: key facts
Table 38: Sanofi SA: Annual Financial Ratios
Table 39: Sanofi SA: Key Employees
Table 40: Sanofi SA: Key Employees Continued
Table 41: Genomma Lab Internacional SAB de CV: key facts
Table 42: Genomma Lab Internacional SAB de CV: Annual Financial Ratios
Table 43: Genomma Lab Internacional SAB de CV: Key Employees
Table 44: Merck & Co., Inc.: key facts
Table 45: Merck & Co., Inc.: Annual Financial Ratios
Table 46: Merck & Co., Inc.: Key Employees
Table 47: Merck & Co., Inc.: Key Employees Continued
Table 48: Pfizer Inc.: key facts
Table 49: Pfizer Inc.: Annual Financial Ratios
Table 50: Pfizer Inc.: Key Employees
Table 51: Pfizer Inc.: Key Employees Continued
Table 52: AstraZeneca PLC: key facts
Table 53: AstraZeneca PLC: Annual Financial Ratios
Table 54: AstraZeneca PLC: Key Employees
Table 55: AstraZeneca PLC: Key Employees Continued
List of Figures
Figure 1: NAFTA countries pharmaceuticals industry, revenue ($bn), 2018-27
Figure 2: NAFTA countries pharmaceuticals industry, revenue ($bn), 2018-22
Figure 3: NAFTA countries pharmaceuticals industry forecast, revenue ($bn), 2022-27
Figure 4: Canada pharmaceuticals market value: $ billion, 2017-22
Figure 5: Canada pharmaceuticals market geography segmentation: % share, by value, 2022
Figure 6: Canada pharmaceuticals market value forecast: $ billion, 2022–27
Figure 7: Forces driving competition in the pharmaceuticals market in Canada, 2022
Figure 8: Drivers of buyer power in the pharmaceuticals market in Canada, 2022
Figure 9: Drivers of supplier power in the pharmaceuticals market in Canada, 2022
Figure 10: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Canada, 2022
Figure 11: Factors influencing the threat of substitutes in the pharmaceuticals market in Canada, 2022
Figure 12: Drivers of degree of rivalry in the pharmaceuticals market in Canada, 2022
Figure 13: Mexico pharmaceuticals market value: $ billion, 2017-22
Figure 14: Mexico pharmaceuticals market geography segmentation: % share, by value, 2022
Figure 15: Mexico pharmaceuticals market value forecast: $ billion, 2022–27
Figure 16: Forces driving competition in the pharmaceuticals market in Mexico, 2022
Figure 17: Drivers of buyer power in the pharmaceuticals market in Mexico, 2022
Figure 18: Drivers of supplier power in the pharmaceuticals market in Mexico, 2022
Figure 19: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Mexico, 2022
Figure 20: Factors influencing the threat of substitutes in the pharmaceuticals market in Mexico, 2022
Figure 21: Drivers of degree of rivalry in the pharmaceuticals market in Mexico, 2022
Figure 22: United States pharmaceuticals market value: $ billion, 2017-22
Figure 23: United States pharmaceuticals market geography segmentation: % share, by value, 2022
Figure 24: United States pharmaceuticals market value forecast: $ billion, 2022–27
Figure 25: Forces driving competition in the pharmaceuticals market in the United States, 2022
Figure 26: Drivers of buyer power in the pharmaceuticals market in the United States, 2022
Figure 27: Drivers of supplier power in the pharmaceuticals market in the United States, 2022
Figure 28: Factors influencing the likelihood of new entrants in the pharmaceuticals market in the United States, 2022
Figure 29: Factors influencing the threat of substitutes in the pharmaceuticals market in the United States, 2022
Figure 30: Drivers of degree of rivalry in the pharmaceuticals market in the United States, 2022
